Drug Trial Radar · NCT07199413
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 15, 2026
Primary completion
Apr 1, 2029
Study completion Apr 1, 2029
Sponsor
- Lead sponsor
- Medical College of WisconsinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.
Conditions
- Brain Metastases
- Leptomeningeal Metastasis
Interventions
SV-BR-1-GM VaccineBiological
\~20 X 10\^6 cells across 4 injection sites
CyclophosphamideDrug
300 mg/m\^2 Intravenous
PembrolizumabDrug
200 mg/m\^2 Intravenous
InterferonDrug
0.18 mcg subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Grade 3 or higher adverse eventsTime frame: 30 days after the beginning of study therapy, 9 months after the beginning of study therapy
- Study therapy durationTime frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.